{
    "1adc970c-d433-44d0-aa09-d3834986f7a2": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00066573",
        "Statement": "两个主要试验群体的结果之间有 13.2% 的差异",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15,
            16,
            17
        ]
    },
    "6b9162d0-0816-46d4-81af-c60028dcc63b": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00425854",
        "Secondary_id": "NCT01224678",
        "Statement": "显著增加排泄率的患者被排除在初级试验中,但如果他们55岁或以上,他们仍然可以参加次级试验。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            15
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15,
            16
        ]
    },
    "0b6cc8e3-69ee-4a91-b93d-2ad3fddce65f": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT02273973",
        "Secondary_id": "NCT00281697",
        "Statement": "二级试验和初级试验中有相当数量的参与者患有内膜炎",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            5,
            18
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15,
            16,
            17,
            18,
            19,
            20,
            21,
            22,
            23
        ]
    },
    "cc1f712a-2116-4e40-9810-f315e3fa5ff8": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00593346",
        "Statement": "初级试验没有报告其患者群体的PFS或客观反应率",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3
        ]
    },
    "904061c0-14fa-4f13-9118-9a41e24fa8eb": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT02340221",
        "Statement": "此前用Fulvestrant或用磷酸乙烯酸三基纳酶(PI3K)抑制剂的治疗不会阻止患者参加初级试验。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            13
        ]
    },
    "43ee7645-ce1e-42d5-9a74-3e379f6f367b": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00281697",
        "Statement": "只有具有 HER2 阳性状态的患者才能参加初级试验。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            13
        ]
    },
    "0cef8c8e-7986-46c7-a597-c5733a9899c0": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00915603",
        "Statement": "最短的PFS在初级试验的群体1不到7个月,在群体2最短的群体仅超过7个月",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15
        ]
    },
    "43ce26e5-03fa-4e9d-b0eb-6ea356295753": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT01998906",
        "Statement": "初级试验的两个群体共经历了17个周期,每个周期持续3周。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12
        ]
    },
    "3facad41-0221-42f8-834d-470e65c4aad5": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00428922",
        "Statement": "初级试验的结果测量是治疗期间和治疗后患者与疾病存活的时间长度",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1
        ]
    },
    "9cbc00e9-3a2d-4471-a93e-72c95132fb6a": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01912612",
        "Statement": "初级试验中唯一发生心脏衰竭的病例发生在1组中",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5
        ]
    },
    "8b91cab9-d858-45f3-bf8d-3d6fc55b4818": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT02419807",
        "Statement": "主要试验结果部分报告两个不同的测量",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10
        ]
    },
    "4a75574c-fa86-4e62-a210-81c7b98a3807": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00022516",
        "Statement": "T4 N2 M4患者有资格参加初级试验",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            2
        ]
    },
    "d0b50aeb-aad8-4a8d-aae6-5c58a7d382c7": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT02419807",
        "Statement": "主要试验结果部分报告了两种不同的测量,对于所有3个群体。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10
        ]
    },
    "b0b61978-57db-4a1c-812c-509e8b05f2dc": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT03098550",
        "Statement": "初级试验的两群人接受相同的干预,两群人之间的区别在于患者的癌症类型。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5
        ]
    },
    "24b85b44-b9e6-4c28-b3aa-1bd97102b7f1": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01929395",
        "Statement": "患者必须有可触摸的癌症,以被纳入初级试验",
        "Label": "Entailment",
        "Primary_evidence_index": [
            2
        ]
    },
    "fbb62216-2cf2-4813-ad41-12a86940610f": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT03176238",
        "Statement": "贫血是初级试验1和2组中最常见的不良事件。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15,
            16,
            17,
            18,
            19,
            20,
            21,
            22,
            23
        ]
    },
    "961a956e-fece-4baa-a2ad-d3a5320bd9d2": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT01644890",
        "Statement": "初级试验的1组中最短的PFS短于3周",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10
        ]
    },
    "97fd111c-6969-43ab-93af-b3dff09960e5": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00328783",
        "Statement": "初级试验中的不良事件部分报告了12个不同的Aes的发病率",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1
        ]
    },
    "eb1bfb08-eba0-4130-b328-00f56c0f84a6": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00191789",
        "Secondary_id": "NCT00876395",
        "Statement": "腹泻是初级试验和次级试验中最常见的不良事件",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15,
            16,
            17,
            18,
            19,
            20,
            21,
            22,
            23
        ]
    },
    "b1219e71-fbf5-4bba-8a93-a27ae444e3e1": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00274469",
        "Statement": "为了符合初级试验的条件,患者必须被诊断出具有激素受体阳性先进乳腺癌,但可能没有接受过此前的治疗。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3
        ]
    },
    "f10f3b84-e039-4a02-a98b-86d149d9a16f": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00438100",
        "Statement": "对初级试验的参与者不允许继续服用氟细胞素治疗",
        "Label": "Entailment",
        "Primary_evidence_index": [
            29
        ]
    },
    "0ddb07ae-6e70-436d-8723-f609e59c57da": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT01118624",
        "Statement": "初级试验参与者接受基于体重计算的 Pralatrexate 剂量",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2
        ]
    },
    "c10eea1a-5768-442d-ae07-20b4f8f4b583": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT02924883",
        "Statement": "只有三负乳腺癌患者才有资格参加初级试验",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            3
        ]
    },
    "2ef186d0-b4ab-44de-b785-a63e9e95851a": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT02273973",
        "Secondary_id": "NCT00281697",
        "Statement": "二级试验和初级试验中的大多数参与者没有患有内膜炎。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            5,
            18
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15,
            16,
            17,
            18,
            19,
            20,
            21,
            22,
            23
        ]
    },
    "fef5aedb-21c0-4130-b8a3-cb1df5017c7a": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00328783",
        "Statement": "初审中的不良事件部分是空的",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1
        ]
    },
    "2655c892-216e-4b96-a8f2-6f64403215c5": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01905592",
        "Statement": "有4种类型的不良事件,不影响初级试验1组中的任何患者",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12
        ]
    },
    "2825d63b-8f22-4fb8-829f-9567845251c6": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT02186015",
        "Statement": "成年人和儿童可参加初审",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            5
        ]
    },
    "6b35bc10-f591-4b84-abac-40a74be949fa": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT02340221",
        "Statement": "此前用Fulvestrant或用磷酸乙烯酸三基纳酶(PI3K)抑制剂的治疗不适用于初级试验。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            13
        ]
    },
    "a5baab2c-9c32-4301-a574-4ba5a0c2eb00": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01439945",
        "Secondary_id": "NCT01998906",
        "Statement": "在研究登记前至少4个月的热潮的存在是所有希望参加初级试验或次级试验的患者的要求。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            3
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3
        ]
    },
    "70677d5f-7022-404c-8410-d1f89366d92f": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT00856492",
        "Secondary_id": "NCT00009945",
        "Statement": "二级试验和初级试验都测量了患者群体的pCR和肿瘤直径。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3
        ]
    },
    "f46a7d27-a94f-4389-a1a0-4a8f5177b354": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT02679755",
        "Statement": "在初级试验中记录的任何单独AES都不会影响超过一个患者。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11
        ]
    },
    "fe876bb0-7ce3-4197-81ad-920f1f77938e": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00066573",
        "Statement": "两个主要试验群体的结果之间存在最小的差异",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15,
            16,
            17
        ]
    },
    "f45ff82d-e0f5-456a-9d78-ddc2dc6ab929": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00121992",
        "Statement": "候选人必须年满18岁,具有严重残疾和足够的肝脏,肾脏和心脏功能以及足够的血液学水平。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            7,
            8,
            9,
            10
        ]
    },
    "4f705481-5dd0-414c-b375-c56e8c235b42": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01042535",
        "Statement": "初级试验中最常见的不良事件是皮肤感染",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12
        ]
    },
    "614d7ade-0fa7-4d77-bc19-1d3a2f2f48c2": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00924352",
        "Statement": "发烧性中毒性是初级试验中记录的最常见不良事件,影响了该试验中的大多数患者。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11
        ]
    },
    "c09fa61c-967a-40ae-96b0-c87b7cde237b": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT02679755",
        "Statement": "在初级试验中记录的任何单独AES都不会影响超过10%的人口。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11
        ]
    },
    "4309860d-042d-45a4-8a0a-a9fdd075247a": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT02915744",
        "Statement": "初级试验的 1 和 2 组未通过注射接收 NKTR-102",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5
        ]
    },
    "f2275929-7cfe-4bb1-a9f6-6bd0c4d5bf85": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT01262027",
        "Secondary_id": "NCT02301988",
        "Statement": "初级试验和次级试验使用相同的结果测量",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3
        ]
    },
    "59cd7909-00c3-4c23-9a08-a42dbc8eabdd": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00503906",
        "Statement": "初级试验的参与者不会接受一定数量的周期干预,周期会持续到疾病进展",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5
        ]
    },
    "e6a4e9a6-56b8-4a30-9743-eb02688c090f": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00550771",
        "Statement": "患有乳腺肿瘤T2 N2 M0节点阳性患者将有资格参加初级试验,就像患有肿瘤直径为1.5cm的乳腺肿瘤节点阳性患者一样。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            5,
            6,
            7,
            8
        ]
    },
    "82a3e542-f784-44d7-90f6-34d7e969283c": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00240071",
        "Statement": "初级试验参与者在研究期间服用多于一种类型的药物",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2
        ]
    },
    "fb360514-14be-45ab-8b74-ea5a7eb181d7": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01852032",
        "Secondary_id": "NCT01830933",
        "Statement": "初级试验和次级试验没有报告不良事件。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3
        ]
    },
    "7137dec6-5c98-4156-8035-7bbaaf0b649d": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01125566",
        "Statement": "ECOG 得分 < 2 是必要的,以获得初级试验的资格",
        "Label": "Entailment",
        "Primary_evidence_index": [
            8
        ]
    },
    "015dd869-db90-45a9-a951-9dc7dc2b2e01": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00063570",
        "Statement": "患有恶性脑肿瘤或结肠癌诊断的患者有资格参加初级试验",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            8
        ]
    },
    "3a4003f6-ff1c-43d8-be48-f767266b2cf5": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00820170",
        "Secondary_id": "NCT00263588",
        "Statement": "二级审判和初级审判不具备相同的包括和排除条件",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15,
            16,
            17,
            18,
            19,
            20,
            21,
            22,
            23,
            24,
            25,
            26,
            27,
            28,
            29,
            30,
            31,
            32,
            33,
            34,
            35,
            36,
            37,
            38,
            39,
            40,
            41,
            42,
            43,
            44,
            45,
            46,
            47,
            48,
            49,
            50,
            51,
            52,
            53,
            54,
            55,
            56,
            57,
            58,
            59,
            60,
            61,
            62,
            63,
            64,
            65,
            66
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15
        ]
    },
    "47ba01d6-edc7-4acb-ab49-b0e86f4eeaf7": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00915603",
        "Statement": "初级试验中至少有2名参与者,每个群体至少有1名,无进展生存期为10.8个月。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15
        ]
    },
    "f3cb9150-32c6-4877-9a87-4fac45a24948": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00450723",
        "Secondary_id": "NCT00290758",
        "Statement": "在二级试验和初级试验之间,所有记录的肌肉骨骼不良事件发生在二级试验的群体2中。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15,
            16,
            17
        ]
    },
    "9d8b26d6-d574-4717-88b6-77458bc683f3": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00733408",
        "Statement": "Syncope是初级试验中记录的最常见的不良事件",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5
        ]
    },
    "51be7c95-8da4-419c-950c-91ebdd2c3fe5": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT01572727",
        "Secondary_id": "NCT00328783",
        "Statement": "所有初级试验的患者都获得比二级试验的患者更高的BKM120剂量。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3
        ]
    },
    "07042b0f-d422-49c3-8d53-81319927a4b3": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00121134",
        "Secondary_id": "NCT03098550",
        "Statement": "所有初级试验的参与者都有历史学上或细胞学上确认的2级或3级侵入性乳腺癌,没有进入二级试验所需的特定癌症阶段。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            1
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10
        ]
    },
    "32361e21-ee57-4c34-9390-833ba5048a10": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00570921",
        "Statement": "初级试验参与者将Fulvestrant注射到肌肉(到海豚)和Everolimus口服",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3
        ]
    },
    "88668508-dfd4-4a39-91cd-cf1654a6dfc4": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00593346",
        "Statement": "初级试验没有报告PFS或其患者群体的客观反应率,而是报告患有皮肤炎的患者比例",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3
        ]
    },
    "dca4c9f7-bb2a-4f73-b390-93b7ced87c73": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT00503750",
        "Secondary_id": "NCT00005879",
        "Statement": "二级试验和初级试验的结果不可比拟",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4
        ]
    },
    "e7604382-09cd-43b4-998f-a51b33f25c5a": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT00290732",
        "Secondary_id": "NCT00232505",
        "Statement": "初级试验和次级试验的参与者没有口服任何药物。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6
        ]
    },
    "75affd49-4905-4d43-9a5c-ef795281bac4": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00193037",
        "Statement": "初级试验中的任何干预都没有导致超过40%的患者获得客观效益。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15,
            16,
            17,
            18
        ]
    },
    "2e76c74a-b6dd-47d8-a674-c1e80b0a3a65": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00274469",
        "Statement": "为了符合初级试验的条件,患者必须被诊断为激素受体阳性前进的乳腺癌,并已接受此类癌症的先前化疗。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3
        ]
    },
    "8c6314f7-34f5-42a7-ba66-b95d050a6315": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT01644890",
        "Statement": "初级试验的1组中最短的PFS低于平均水平的 1.4 个月",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10
        ]
    },
    "f114846e-79d8-4712-add0-bb34b65d418f": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00357110",
        "Statement": "在初级试验的1号群体中记录了6例死亡,在2号群体中记录了7例死亡。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15
        ]
    },
    "812bd63c-4bfb-49cb-8fa9-baa3f8f6dabe": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT01416389",
        "Statement": "初级试验报告了其群体中患者的病变数量的变化。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2
        ]
    },
    "b1d28450-fc7d-496a-9c7c-bf711b28f8e4": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00876395",
        "Statement": "所有接受初级试验的孕妇都接受过内分泌治疗的乳腺癌预先治疗",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            7,
            6
        ]
    },
    "c7dc582a-4a58-4cb5-b980-b2d2b6a128c3": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00331630",
        "Statement": "在初级试验中没有记录心脏或神经不良事件。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3
        ]
    },
    "a805f174-2707-4302-a195-05153ea8523e": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT02186015",
        "Statement": "只有成年人可以参加初审",
        "Label": "Entailment",
        "Primary_evidence_index": [
            5
        ]
    },
    "e4aeb013-7713-4b73-acbd-f8379cc6a494": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00005879",
        "Statement": "在初级试验的群体2中,与群体1的群体2中有较高的滑盘患者百分比",
        "Label": "Entailment",
        "Primary_evidence_index": [
            5,
            16
        ]
    },
    "b8eaa8fd-61cf-4ca9-aaec-267d61c1fae3": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT01808573",
        "Statement": "所有初级试验1组的患者都有7个月以上的PFS,最高的PFS在10个月以下。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9
        ]
    },
    "2729a321-709b-4392-9604-dd7237bedb17": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00093795",
        "Statement": "初级试验1和2组的大多数参与者在5年内实现了无疾病生存。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15,
            16,
            17,
            18,
            19,
            20,
            21,
            22,
            23,
            24,
            25
        ]
    },
    "8e9611fc-89f8-44cb-af09-8d71a13ca082": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT02915744",
        "Statement": "初级试验的 1 和 2 组不接受相同的干预",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5
        ]
    },
    "b9491012-49ba-4eb1-8230-1966f54ea012": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00617539",
        "Statement": "患有骨外转移的患者可能有资格参加初级试验",
        "Label": "Entailment",
        "Primary_evidence_index": [
            2
        ]
    },
    "62e449ad-16b3-479d-94a5-ffc435b5e99c": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00063570",
        "Statement": "患有恶性脑肿瘤诊断的患者被排除在初级试验中",
        "Label": "Entailment",
        "Primary_evidence_index": [
            8
        ]
    },
    "565d7982-aa9a-4c01-987c-1d67bc9c212d": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00438100",
        "Statement": "所有初级试验参与者都需要继续服用氟细胞素治疗,治疗必须在研究入学前至少6个月开始。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            29
        ]
    },
    "7271e0db-bb82-423f-ad95-5ffa84fab97e": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01216176",
        "Secondary_id": "NCT00325234",
        "Statement": "在初级试验中有更多的Urosepsis病例,而不是在次级试验中",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            8
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15,
            16,
            17,
            18,
            19,
            20,
            21,
            22,
            23,
            24,
            25
        ]
    },
    "6402e13a-7cfb-4774-b7f9-80ecb79fda2a": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT01011946",
        "Secondary_id": "NCT00066573",
        "Statement": "初级试验参与者不服用任何口服药物,而二级试验患者只接受口服治疗。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7
        ]
    },
    "734423d5-4b47-4448-ab98-811015d626f0": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01307891",
        "Statement": "在初级试验中的两组中,有多个患者患有中性衰竭。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            6,
            7,
            8
        ]
    },
    "e9fd065c-342c-4dfb-9c1c-a4c0c44d0acd": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT00612560",
        "Secondary_id": "NCT01216176",
        "Statement": "所有初级试验参与者均以药丸形式服用阿纳斯特拉佐尔,但二级试验中没有人接受任何阿纳斯特拉佐尔。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4
        ]
    },
    "32ed503c-1cfd-44f6-b8bb-23d9d175d73d": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00572728",
        "Statement": "患者必须能够接受PET扫描才能参加初级试验",
        "Label": "Entailment",
        "Primary_evidence_index": [
            5
        ]
    },
    "175044aa-72b1-405d-8506-30002f5098e4": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00606931",
        "Statement": "在初级试验中,有不良事件部分描述了参与研究时患有低血压、出血和心脏病的患者数量。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1
        ]
    },
    "045ad91e-44fa-42cc-ac22-a7aab26a9009": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00240071",
        "Statement": "主要试验参与者作为干预的一部分接受了Avastin、Bevacizumab和放射治疗。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2
        ]
    },
    "00822101-fa21-4a26-bf45-3b1f535da005": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00281697",
        "Statement": "具有 HER2 阳性状态的患者不能参加初级试验。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            13
        ]
    },
    "06f798d1-2956-4903-83e9-58a41fa425f7": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01830933",
        "Secondary_id": "NCT00852930",
        "Statement": "初级试验和次级试验没有记录任何与心脏或感染有关的不良事件。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3
        ]
    },
    "8648c7df-582a-42a9-9330-414b2430ac56": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00009945",
        "Statement": "初级试验中的任何个别不良事件都不会影响100多名患者,总计不到30名患者会出现不良事件。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15,
            16,
            17,
            18,
            19,
            20,
            21
        ]
    },
    "89f610a7-9e81-43a4-8c1e-5503233b2be1": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01596751",
        "Statement": "乳腺癌患者必须有记录的稳定疾病才能参加初级试验",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            1
        ]
    },
    "b0046821-ba27-4a90-8869-cb708b843aa4": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT00612560",
        "Secondary_id": "NCT01216176",
        "Statement": "所有初级试验参与者都接受了种子,但二级试验中没有人接受过任何种子。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4
        ]
    },
    "d1b217ae-76f3-4ba6-958e-5b2558703ba4": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01912612",
        "Statement": "在初级试验中,多起心脏衰竭的病例发生在1组中,但在2组中没有发生。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5
        ]
    },
    "8ddf8b88-6e06-4c71-9e28-45f73a637af0": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT01011946",
        "Secondary_id": "NCT00066573",
        "Statement": "初级试验参与者服用口服和局部药物,而二级试验患者只接受口服治疗。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7
        ]
    },
    "0ea29bd5-20be-40ea-8ad7-705d283d1d48": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00093795",
        "Statement": "初级试验1和2组的大多数参与者患有某种疾病复发、反面乳腺癌、第二次初级癌症、复发前任何原因死亡或第二次初级癌症。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15,
            16,
            17,
            18,
            19,
            20,
            21,
            22,
            23,
            24,
            25
        ]
    },
    "e147796d-2edd-42d1-ac53-300fb8bd5eb6": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00374322",
        "Statement": "初级试验中的80%的患者接受了安慰剂干预",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5
        ]
    },
    "6b33b4ae-36f2-4a53-a954-6f246f6e023d": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT02445586",
        "Statement": "希望参加初级试验的患者必须具有已知和记录的HER2+状态和至少50%的LVEF(%)",
        "Label": "Entailment",
        "Primary_evidence_index": [
            3,
            4
        ]
    },
    "06fad978-1dc3-46f5-b45f-5ac6577f28b9": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00325234",
        "Secondary_id": "NCT00274469",
        "Statement": "患者必须是女性,并已确认先进的结肠癌,以符合二级试验和初级试验的资格",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1
        ],
        "Secondary_evidence_index": [
            0,
            1
        ]
    },
    "878c09e7-3fd9-404e-921e-5b549e9578fb": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT02658734",
        "Statement": "主要试验中的大多数患者经历了1级不良事件,最常见的严重程度为4级。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13
        ]
    },
    "3a0c517d-9b9a-4497-9675-50ff12cd02b7": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT02131064",
        "Statement": "在初级试验的1组中,左腹部功能障碍的病例比腹痛的病例多。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            8,
            9
        ]
    },
    "9abb10d7-496e-44fd-915d-d86aedf6c9b6": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT02445586",
        "Statement": "希望参加初级试验的患者必须具有已知和记录的TNBC状态和至少50%(%)的LVEF。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            3,
            4
        ]
    },
    "8460a212-8054-4bd2-b4e6-af1d137a2f79": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT03012477",
        "Secondary_id": "NCT02419807",
        "Statement": "初级试验和次级试验使用不同的衡量单位报告其结果",
        "Label": "Entailment",
        "Primary_evidence_index": [
            11
        ],
        "Secondary_evidence_index": [
            9
        ]
    },
    "a3390ae6-d41d-4dc7-899e-de9534adfd6b": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00477464",
        "Statement": "初级试验的参与者获得了显著高剂量的卡佩西塔宾比拉帕提尼布。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2
        ]
    },
    "17bbea92-8f92-41f3-9b9d-cf6e62cf6798": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00445458",
        "Statement": "初级试验报告了与帕克利塔克塞尔相结合治疗的纳拉提尼布患者的百分比,这些患者的副作用足够严重,以防止剂量或治疗水平的增加。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3
        ]
    },
    "794269ca-e7ec-4a65-ace5-b0f24a8cdc15": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT00633464",
        "Secondary_id": "NCT01644890",
        "Statement": "初级试验测量与客观响应的群体中的参与者的百分比,而次级试验测量PFS",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4
        ]
    },
    "4dfff980-6a2b-4f01-9194-6ec831d6fed7": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00733408",
        "Statement": "感染是初级试验中记录的最常见的不良事件",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5
        ]
    },
    "dc4c57b0-8c75-494e-81b0-3528df85ebff": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT00852930",
        "Secondary_id": "NCT02915744",
        "Statement": "二级试验或初级试验都没有记录他们的群体中患者的总生存率(OS)。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3
        ]
    },
    "8d9f94e3-871b-4fb4-a522-0a73d9d0ec3c": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT00305448",
        "Secondary_id": "NCT00425854",
        "Statement": "二级试验和初级试验使用客观响应作为其干预的结果测量,但它们使用了完全响应的不同定义。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3
        ]
    },
    "251a20d8-2555-4929-9d01-c02311bdc93f": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00754325",
        "Statement": "患病进展或死亡的患者在初级试验的2组比在1组的比例更高。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15,
            16,
            17,
            18
        ]
    },
    "dd2f3c3d-fa95-4fca-a3f0-795fd4f3abf1": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT00852930",
        "Secondary_id": "NCT02915744",
        "Statement": "二级试验和初级试验在其结果部分中不记录相同的指标",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3
        ]
    },
    "f0273b8c-460d-46fe-9c52-8ff4b08e439b": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00127933",
        "Statement": "伊利安是一名56岁的女性,伊丽莎白是一名32岁的女性,伊利安和伊丽莎白都可以参加初审。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1
        ]
    },
    "bc2024fc-5b39-4fa6-badf-f034d6fe8bb8": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01596751",
        "Statement": "乳腺癌患者必须有记录进展性疾病才能参加初级试验",
        "Label": "Entailment",
        "Primary_evidence_index": [
            1
        ]
    },
    "c2217d42-e90c-4ffe-b084-e653b9ace4d5": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01830933",
        "Secondary_id": "NCT00852930",
        "Statement": "初级试验和次级试验没有记录任何与心脏或感染有关的不良事件,但它们都记录了几例癫痫。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3
        ]
    },
    "080da381-b5dd-46d3-99c4-18112da153c1": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT02244580",
        "Secondary_id": "NCT03176238",
        "Statement": "急性心脏病发作、心肺衰竭和超心室心脏病发作的病例在二次试验的1组中少于初级试验的2组中。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3
        ],
        "Secondary_evidence_index": [
            0,
            16,
            20,
            22
        ]
    },
    "c100a7cd-e3a2-4901-a3e0-12336f769c7b": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00258960",
        "Secondary_id": "NCT00121992",
        "Statement": "二级试验报告了1例结膜炎病例,而初级试验报告了16例。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8
        ],
        "Secondary_evidence_index": [
            0,
            9,
            14,
            23
        ]
    },
    "ec1e269e-470d-43d9-8f23-8a19a5c96fcc": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT03176238",
        "Statement": "贫血是初级试验组1中最常见的不良事件,甲状心脏是组2中最常见的。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15,
            16,
            17,
            18,
            19,
            20,
            21,
            22,
            23
        ]
    },
    "21611c2a-e6eb-4012-a209-9b6781e1f260": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00606931",
        "Statement": "初审中没有不利事件部分",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1
        ]
    },
    "d1b7105d-0b7d-4b10-92a7-d63243ff0629": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00425854",
        "Secondary_id": "NCT01224678",
        "Statement": "显著低排泄率的患者被排除在初级试验中,但如果他们年龄为55岁或更年轻,他们仍然可以参加次级试验。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            15
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15,
            16
        ]
    },
    "7f3fe97e-68ee-470f-b06e-21cdddb67aa8": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00121134",
        "Secondary_id": "NCT03098550",
        "Statement": "所有初级试验的参与者都有细胞学上确认的第3阶段侵入性乳腺癌,没有进入二级试验所需的特定癌症阶段。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            1
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10
        ]
    },
    "ce8464bd-951e-44aa-97d9-10b917b055ce": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00005879",
        "Statement": "在初级试验的群体2中,与群体1的群体1相比,具有滑动磁盘的患者比例显著高。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            5,
            16
        ]
    },
    "0131ebe3-746b-45a5-ba60-fdd326974fec": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT01262027",
        "Secondary_id": "NCT02301988",
        "Statement": "初级试验和次级试验使用可比较的结果测量",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3
        ]
    },
    "b1dd7632-ed92-40a9-9293-bce68619c658": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00376597",
        "Statement": "四级癌症患者被排除在初级试验中,只有二级和三级癌症患者才有资格。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1
        ]
    },
    "45ccd2c8-6e02-4f0f-a370-eed18d26e6dc": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00570921",
        "Statement": "主要试验参与者注射了Fulvestrant肌肉和Everolimus口服。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3
        ]
    },
    "4a15ec5e-4904-4f01-a0a2-c51e83c8c070": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT01042938",
        "Statement": "初级试验报告了 Curcumin C3 综合群体和安慰剂群体的辐射治疗场所中的皮肤炎的严重性",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15
        ]
    },
    "b9e29ea8-6847-40d4-b5c3-81c496101695": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT01808573",
        "Statement": "所有初级试验1组的患者都有超过8.8个月的PFS,最高的PFS只有不到10个月。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9
        ]
    },
    "2a2c16a7-f427-4fdb-8153-94aac304e4b8": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT01998906",
        "Statement": "两组初级试验共接受17个周期,每周持续3周,患者在所有17个周期中接受相同的类型和剂量药物。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12
        ]
    },
    "618a3ae1-b22c-4c35-86a6-190c1b5b5d21": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00375427",
        "Statement": "患者必须有至少1年的预期寿命才能参加初级试验",
        "Label": "Entailment",
        "Primary_evidence_index": [
            6
        ]
    },
    "e62f5a3f-0091-4980-9822-db8f4dc2502a": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT01042938",
        "Statement": "初级试验报告了 Curcumin C3 复合体和安慰剂复合体的辐射治疗场所中的皮肤炎的严重性,这两个复合体的结果没有差异",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15
        ]
    },
    "4a41ac73-538a-43e5-b7ce-8c8e2d56286e": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00290758",
        "Secondary_id": "NCT02370238",
        "Statement": "目前接受内分泌治疗的女性被排除在二级试验和初级试验中,除非他们正在接受辅助治疗。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            45,
            46
        ],
        "Secondary_evidence_index": [
            18,
            19,
            20
        ]
    },
    "75a65913-5655-4377-b441-ecdd4dd75175": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00376597",
        "Statement": "四级癌症患者被排除在初级试验中",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1
        ]
    },
    "1329dec6-fb2c-4219-9db6-3fef9d94b316": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT02131064",
        "Statement": "在初级试验的1组中,左腹部功能障碍的病例比腹部疼痛多10例。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            8,
            9
        ]
    },
    "29b2fa29-5a76-4877-95bb-1a8de7973d33": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00191815",
        "Statement": "初级试验1组中只有6/67名患者遭受不良事件",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1
        ]
    },
    "7edba90d-076d-4f55-b9d6-a1765ceb48bd": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT00290732",
        "Secondary_id": "NCT00232505",
        "Statement": "初级试验和次级试验的参与者不服用任何药物",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6
        ]
    },
    "ba9daeb9-796d-49ab-a30c-4d8acbdf4d37": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00754325",
        "Statement": "在初级试验中,接受Fulvestrant的患者比接受Herceptin的患者更有可能患病进展或死亡。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15,
            16,
            17,
            18
        ]
    },
    "1314146f-2869-4525-8034-7f732d238385": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00009945",
        "Statement": "初级试验中的任何个别不良事件都不会影响100多名患者。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15,
            16,
            17,
            18,
            19,
            20,
            21
        ]
    },
    "7c7418d2-32d7-4517-874b-eb3db24ea16a": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00121992",
        "Statement": "为了获得初级试验资格,候选人必须年满18岁,具有超过80的卡诺夫斯基分数和足够的肝脏,肾脏和心脏功能以及足够的血液学水平。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            7,
            8,
            9,
            10
        ]
    },
    "1f6a14ae-e22b-4b40-b389-217570dbf38e": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00900627",
        "Statement": "初级试验中 50% 的 2 组患者患有剂量限制性毒性",
        "Label": "Entailment",
        "Primary_evidence_index": [
            15,
            16,
            17,
            18,
            8,
            20,
            21,
            22,
            12,
            13,
            14
        ]
    },
    "5c1e360c-fd93-4dd4-b855-71ba416d34cb": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00263588",
        "Statement": "患者必须能够口服药物参加初级试验",
        "Label": "Entailment",
        "Primary_evidence_index": [
            7
        ]
    },
    "c7a953b0-ac96-4e0a-9c1d-98cf8af2861d": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01852032",
        "Secondary_id": "NCT01830933",
        "Statement": "初级试验和次级试验报告相同类型的不良事件",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3
        ]
    },
    "48f516ff-abb4-4312-9b00-02f53fb16218": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00944047",
        "Statement": "在干预手臂中的四分之一的初级试验患者经历了病理综合反应",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15,
            16,
            17
        ]
    },
    "978d19fc-e7f6-485e-b8bd-cfcde06441ab": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00022516",
        "Statement": "T1 N0 M0 患者有资格参加初级试验",
        "Label": "Entailment",
        "Primary_evidence_index": [
            2
        ]
    },
    "0a6d1b4c-244e-44e2-a229-62e4cbdfa979": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT01581619",
        "Secondary_id": "NCT00106002",
        "Statement": "二级试验和初级试验的结果是不可比的。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3
        ]
    },
    "9bcc31df-c1f6-4785-9235-f673213acf3a": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00333775",
        "Statement": "两组初级试验小组都接受相同的Docetaxel剂量",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5
        ]
    },
    "63a0a9fc-80b9-450f-b2c6-7aee37ce26a9": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00904033",
        "Statement": "初级试验中的任何一群人都不需要接受手术或作为干预的一部分接受任何口服药物。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6
        ]
    },
    "75cf4ec2-9f2b-4d5b-8772-af247eaca07b": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00232505",
        "Statement": "histologically 确认的乳腺癌 I-III 阶段的患者不符合初级试验的条件",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2
        ]
    },
    "553f00ea-5197-4233-b1e0-e5727856b599": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00331630",
        "Statement": "在初级试验中没有记录与心脏或肠道相关的不良事件。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3
        ]
    },
    "57b2ae97-0d1d-4d5d-bc4b-109e8e5acb32": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01224678",
        "Secondary_id": "NCT01042535",
        "Statement": "二级试验中患有精神健康疾病、肺炎、心血管结血症和贫血的病例比初级试验多。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5
        ]
    },
    "215a5c4a-d90c-4500-8284-0679ce311734": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00263588",
        "Statement": "患者必须有HER2乳腺癌才能参加初级试验",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            2
        ]
    },
    "e9a4bd91-f58b-4234-9037-75e0699d1bbd": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT01118624",
        "Statement": "初级试验参与者接受300mg/m^2剂量以下的Pralatrexate",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2
        ]
    },
    "7d52734c-0801-413d-9ae2-d190b972cde5": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT00503750",
        "Secondary_id": "NCT00005879",
        "Statement": "二级试验和初级试验的结果可以通过从几天到几个月的单元进行比较",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4
        ]
    },
    "5de9caeb-9dd5-4535-8fe3-289450d9c626": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00820222",
        "Statement": "初级试验结果表明,Trastuzumab Plus Capecitabine 组的中枢神经元转移病人比 Lapatinib Plus Capecitabine 组的病人比例更高。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15
        ]
    },
    "bebfc78e-b35f-4677-8342-9567a7e795a1": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00091442",
        "Secondary_id": "NCT01439945",
        "Statement": "二级试验中有一个腹泻病例,初级试验中没有",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15,
            16,
            17,
            18,
            19,
            20,
            21,
            22,
            23
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5
        ]
    },
    "faa65e54-aa04-4595-8dae-05cf00b4c887": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT02301988",
        "Statement": "只有初级试验的1组患者被给予Ipatasertib",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5
        ]
    },
    "751fd763-89fa-4d52-8bda-f09b490a5e78": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00357110",
        "Statement": "在初审小组中没有记录过死亡。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15
        ]
    },
    "c40fdf91-9f81-454a-bba9-ec5c950cef6e": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00374322",
        "Statement": "初级试验中的一个患者群体接受了安慰剂干预",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5
        ]
    },
    "31105b43-832b-48bc-a78d-ee90c155ca44": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01439945",
        "Secondary_id": "NCT01998906",
        "Statement": "在研究登记前30天内出现热潮是所有希望参加初级试验的患者所必需的,但不需要进入次级试验。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            3
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3
        ]
    },
    "49ba06b2-576d-4db2-80b6-51673416f2ba": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT01928186",
        "Secondary_id": "NCT02340221",
        "Statement": "初级试验和次级试验测量FLT PET在患者群中净流量常数(Ki)的百分比变化",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4
        ],
        "Secondary_evidence_index": [
            0,
            1
        ]
    },
    "3cb71095-8e01-40dc-bbf5-eeffed55f354": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00232505",
        "Statement": "histologically 确认的乳腺癌 I-IV 阶段的患者不符合初级试验的条件",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2
        ]
    },
    "09fc4356-6154-427e-b710-ed5df6470aff": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00900627",
        "Statement": "初级试验中 50% 的 2 群患者患有炎",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            15,
            16,
            17,
            18,
            8,
            20,
            21,
            22,
            12,
            13,
            14
        ]
    },
    "446f3c69-0de5-475c-a8e2-ff40ece90672": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT02924883",
        "Statement": "只有患有HER2+ve乳腺癌的患者有资格参加初级试验",
        "Label": "Entailment",
        "Primary_evidence_index": [
            3
        ]
    },
    "cdadcb0a-20c5-47f7-a63a-39f5c6f26ae2": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00445458",
        "Statement": "初级试验报告了与帕克利塔克塞尔相结合治疗的尼拉提尼布患者的百分比,有0副作用。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3
        ]
    },
    "f0e845f9-8991-45b5-a520-51e934756f7a": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT00688909",
        "Secondary_id": "NCT00450723",
        "Statement": "主要试验干预涉及一种口服药物,而次要试验干预基于医疗程序。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2
        ]
    },
    "a0065d58-e03b-4dd0-9c81-cbbf651a6d45": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00820170",
        "Secondary_id": "NCT00263588",
        "Statement": "任何符合二级试验资格的患者也将有资格参加初级试验。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15,
            16,
            17,
            18,
            19,
            20,
            21,
            22,
            23,
            24,
            25,
            26,
            27,
            28,
            29,
            30,
            31,
            32,
            33,
            34,
            35,
            36,
            37,
            38,
            39,
            40,
            41,
            42,
            43,
            44,
            45,
            46,
            47,
            48,
            49,
            50,
            51,
            52,
            53,
            54,
            55,
            56,
            57,
            58,
            59,
            60,
            61,
            62,
            63,
            64,
            65,
            66
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15
        ]
    },
    "b2cdbcb8-de26-4a44-8a94-dd68c13f7e41": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01125566",
        "Statement": "ECOG 得分 > 2 是必要的,以获得初级试验的资格",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            8
        ]
    },
    "973f090a-8967-4d75-bb8e-6166c868337c": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT02301988",
        "Statement": "初级试验中的1组患者服用了比2组患者更高的Ipatasertib和Placebo剂量",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5
        ]
    },
    "79ca2ee8-6c9c-40e6-a87c-925b50d3d3d2": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01929395",
        "Statement": "患者必须在胃和颈部区域有几个可见的癌症,以被纳入初级试验",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            2
        ]
    },
    "1d1f57f8-85f7-448c-a4bb-15957da568fd": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00106002",
        "Statement": "初级试验干预协议将继续进行,直到患者达到完整的反应或疾病进展",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2
        ]
    },
    "9f7d476e-9db3-4c00-abe6-4c2f0160470a": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00944047",
        "Statement": "在干预手臂中的初级试验患者中,不到30%的患者经历了病理完整反应",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15,
            16,
            17
        ]
    },
    "a5e388b9-da3c-437e-a6af-7ba76ad8bf1d": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00333775",
        "Statement": "两个初级试验小组都接受了相同剂量的Docetaxel,而小组 1也接受了100 mg/m2的Placebo。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5
        ]
    },
    "3adcc8fc-b76b-407a-a006-729a13f571fb": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT03098550",
        "Statement": "初级试验的两群体都接受相同的干预,两群体之间的差异是患者的癌症类型,1群体都被诊断为HER2阳性癌症,2群体是PR。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5
        ]
    },
    "68379456-775b-463b-bfdb-d8aa42c9124b": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00325234",
        "Secondary_id": "NCT00274469",
        "Statement": "患者必须是女性,并已确认前进的乳腺癌才能符合二级试验和初级试验的资格",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1
        ],
        "Secondary_evidence_index": [
            0,
            1
        ]
    },
    "5d0ccb93-71ec-4079-92c6-d7cbf951a7bb": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00290758",
        "Secondary_id": "NCT02370238",
        "Statement": "目前接受内分泌治疗的女性被排除在二级试验和初级试验中。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            45,
            46
        ],
        "Secondary_evidence_index": [
            18,
            19,
            20
        ]
    },
    "f04d9695-81b8-4d70-877b-59caddf901bd": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00450723",
        "Secondary_id": "NCT00290758",
        "Statement": "在二级试验和初级试验之间,所有记录的 dyspnea 病例发生在二级试验的 1 组中。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15,
            16,
            17
        ]
    },
    "f42e1874-343a-43ed-bb0c-884509c4793c": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT00633464",
        "Secondary_id": "NCT01644890",
        "Statement": "初级试验测量其客观反应群中参与者的百分比,而次级试验测量患有疾病进展(PD)或死亡的参与者数。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4
        ]
    },
    "30483d7e-7703-459c-bd10-e2bd259c2a4f": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01905592",
        "Statement": "有两种类型的不良事件没有影响初级试验1组中的任何患者。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12
        ]
    },
    "7cde9a22-a91f-4feb-892d-7cbd35f96a27": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT01416389",
        "Statement": "初级试验报告了其群体中的患者肿瘤大小的变化。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2
        ]
    },
    "16c29502-4683-4087-9410-ff1b786556f5": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01042535",
        "Statement": "初级试验中最不常见的不良事件是感冒",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12
        ]
    },
    "5c975af8-6b7f-4a5d-b4a6-257c76763ce9": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT02244580",
        "Secondary_id": "NCT03176238",
        "Statement": "急性心脏病发作、心肺衰竭和超心室心脏病发作的病例在二次试验的群体1中比在初级试验的整个患者群体中多。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3
        ],
        "Secondary_evidence_index": [
            0,
            16,
            20,
            22
        ]
    },
    "1c4e3fe3-b5fe-4ea3-8d9e-0ce1502080e7": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT02370238",
        "Statement": "在初级试验的1号群体中有更多的AEs比2号群体。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15,
            16,
            17,
            18,
            19,
            20,
            21,
            22,
            23
        ]
    },
    "8e91e404-086e-4063-8d54-83d1b8ebd969": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00191815",
        "Statement": "初级试验1组中超过六分之一的患者遭受不良事件",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1
        ]
    },
    "b8322b23-a4f6-4cba-9761-be826b509de7": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01224678",
        "Secondary_id": "NCT01042535",
        "Statement": "二级试验中有更多的眼部疾病、腹痛、发烧性中毒和贫血病例,而不是初级试验中。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5
        ]
    },
    "4519d1cf-7f78-4aa8-85d6-ac94f7eb75a3": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00091442",
        "Secondary_id": "NCT01439945",
        "Statement": "在二级试验中只有一个腹泻病例,在初级试验小组中记录了超过14种不同类型的AES。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15,
            16,
            17,
            18,
            19,
            20,
            21,
            22,
            23
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5
        ]
    },
    "4b97a844-8d52-48bb-8eda-ca205268f016": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00375427",
        "Statement": "患者必须有75岁以上的预期寿命才能参加初级试验",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            6
        ]
    },
    "2a03c17f-3afe-40f1-a0db-4b876ee8c700": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT01928186",
        "Secondary_id": "NCT02340221",
        "Statement": "初级试验和次级试验对其结果有非比较的结果测量",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4
        ],
        "Secondary_evidence_index": [
            0,
            1
        ]
    },
    "3ba42f68-a643-4d10-afd0-cbb358d05a6f": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT01572727",
        "Secondary_id": "NCT00328783",
        "Statement": "所有在初级试验中的患者都获得了比在二级试验中的患者更高的Paclitaxel剂量。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3
        ]
    },
    "0a079cca-abde-42cf-9cec-a76e7a380e14": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00904033",
        "Statement": "初级试验中的任何一群都不需要作为干预的一部分接受手术。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6
        ]
    },
    "9c033072-5f94-4d79-af47-126d531f0d6e": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01216176",
        "Secondary_id": "NCT00325234",
        "Statement": "在初级试验中有更多 Holocraneal cephale 和 Catheter - 相关感染的病例,而不是在次级试验中",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            8
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15,
            16,
            17,
            18,
            19,
            20,
            21,
            22,
            23,
            24,
            25
        ]
    },
    "a52b2d4f-0b06-4960-a9c3-88cb92df0980": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00477464",
        "Statement": "初级试验参与者比接受拉帕蒂尼布更少地服用卡佩西塔宾",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2
        ]
    },
    "a792bbac-0e8a-4bf7-9cc5-56fad481e2fb": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00127933",
        "Statement": "艾莉安是一名56岁的女人,亚历克斯是一名32岁的男人,艾莉安和亚历克斯都可以参加初审。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1
        ]
    },
    "1842904b-5371-49ee-b6f4-8831b879098b": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00924352",
        "Statement": "发烧性中性衰退是初级试验中记录的最常见不良事件,影响超过5%的患者。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11
        ]
    },
    "324562e6-2b61-4a07-b937-86f99689f2d5": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00191789",
        "Secondary_id": "NCT00876395",
        "Statement": "腹泻是初级试验中最常见的不良事件,而二级试验中最常见的贫血。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15,
            16,
            17,
            18,
            19,
            20,
            21,
            22,
            23
        ]
    },
    "74e376d7-5713-43f3-93f1-9608059c9547": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00193037",
        "Statement": "初级试验中的任何干预都没有导致超过40%的患者获得客观效益,事实上,接受多塞塔克尔的患者中有超过86%的 liposomal doxorubicin干预患有致命并发症。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15,
            16,
            17,
            18
        ]
    },
    "0e609fad-9a28-4fb6-90b6-32a731e3b02c": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT03012477",
        "Secondary_id": "NCT02419807",
        "Statement": "初级试验和次级试验以百分比报告其结果,但使用不同的衡量单位。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            11
        ],
        "Secondary_evidence_index": [
            9
        ]
    },
    "236780db-9e59-4dc9-8da0-e786287011cf": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00106002",
        "Statement": "初级试验干预协议共持续14天",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2
        ]
    },
    "6d621974-c719-46df-8a50-d94e49583e33": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00876395",
        "Statement": "所有被接受初级试验的患者都接受过内分泌治疗的乳腺癌预先治疗",
        "Label": "Entailment",
        "Primary_evidence_index": [
            6
        ]
    },
    "a9907a2e-254a-45ca-af50-3e44fd2f7af3": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01307891",
        "Statement": "初级试验的两组中有一个中性衰竭病例",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            6,
            7,
            8
        ]
    },
    "40f699a1-fbc6-40de-8e80-85b28f71632f": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT02658734",
        "Statement": "主要试验中的大多数患者经历了1级不良事件,最常见的严重程度为5级,仅影响了8/70名患者。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13
        ]
    },
    "6499b181-7a23-4073-8459-ad46ff02b20f": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00503906",
        "Statement": "初级试验的参与者将接受12周期(28天)的干预。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5
        ]
    },
    "2da13cd4-7189-4f85-be4d-5c1e213ae293": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT02370238",
        "Statement": "初级试验中最常见的AE是非心脏胸部疼痛,影响了1组参与者的5%以下。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15,
            16,
            17,
            18,
            19,
            20,
            21,
            22,
            23
        ]
    },
    "a9bb6de9-c6f8-4c99-81cd-f101cbaab387": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00617539",
        "Statement": "患者必须没有X射线确认的大脑转移才能符合初级试验的条件",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            1
        ]
    },
    "7e5fd062-6ec3-480f-ab0e-e117eba2ffe7": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00217399",
        "Statement": "所有初级试验的患者都实现了所有靶点损伤的消失,目标损伤最长直径的总和减少 >=30%,或肿瘤既没有生长也不会缩小。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10
        ]
    },
    "016943fa-57ea-4293-8131-03292ea1836c": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00550771",
        "Statement": "患有乳腺肿瘤T2 N2 M0节点阳性患者将有资格参加初级试验,就像患有肿瘤直径超过2厘米的乳腺肿瘤节点阳性患者一样。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            5,
            6,
            7,
            8
        ]
    },
    "402f0dbf-cf67-4425-b300-a0a3df4d59d3": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT00305448",
        "Secondary_id": "NCT00425854",
        "Statement": "二级试验和初级试验使用客观响应作为其干预的结果测量。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3
        ]
    },
    "62be4676-099f-4c42-8029-773af8fde6f7": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00572728",
        "Statement": "患者必须在床上或严重残疾才能参加初级试验",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15,
            16,
            17,
            18,
            19,
            20,
            21,
            22,
            23
        ]
    },
    "1180dd58-61b8-4c48-ab00-7d458e68c85b": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT01581619",
        "Secondary_id": "NCT00106002",
        "Statement": "二级试验的结果和初级试验的报告相同的结果",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3
        ]
    },
    "566bdc2d-7c4a-4547-87da-ac81447ecca8": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00820222",
        "Statement": "初级试验结果表明,Trastuzumab Plus Capecitabine 组患有 3 级或 4 级皮肤/皮下或肺部毒性患者的先例比 Lapatinib Plus Capecitabine 组高。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15
        ]
    },
    "d310ec4e-993e-4827-8dc5-9aca053972db": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT00688909",
        "Secondary_id": "NCT00450723",
        "Statement": "主要试验干预涉及一种口服药物,而次要试验干预基于医疗程序。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2
        ]
    },
    "a5617ae4-05a3-42d0-9e14-141de5f8c010": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00258960",
        "Secondary_id": "NCT00121992",
        "Statement": "二级试验报告了1例结膜炎,而初级试验没有报告任何情况。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8
        ],
        "Secondary_evidence_index": [
            0,
            9,
            14,
            23
        ]
    },
    "42d1fcd3-8faa-4065-bbba-42cc90ab67fb": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT00856492",
        "Secondary_id": "NCT00009945",
        "Statement": "二级试验和初级试验都没有测量患者群体的pCR。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3
        ]
    },
    "d01fda83-5dc8-4ad5-92b8-7553dabd7046": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00428922",
        "Statement": "初级试验的结果测量是治疗期间和治疗后,患者与疾病生活的时间长度,但没有恶化",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1
        ]
    },
    "985bc5a0-bc21-447f-92f1-150e23ede3f5": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00217399",
        "Statement": "所有初级试验患者至少减少了目标损伤最长直径的50%",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10
        ]
    }
}